Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Evolution of antibody immunity to SARS-CoV-2

(2021) Christian Gaebler et al.   NATURE

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

(2021) Adam K. Wheatley et al.   Nature Communications

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

(2021) Aziz Sheikh et al.   LANCET

Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study

(2021) Andrew Hayward et al.   BMJ Open

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

(2020) Mark Ainsworth et al.   LANCET INFECTIOUS DISEASES

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE